N

ovartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.

A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision on approval by Oct. 3.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

    • Yes, CTL019 can work against any malignancy that expresses CD19, which would be any B cell malignancy such as ALL, CLL, and various B cell lymphomas. It also works against multiple myeloma, but they are not certain why it works. It either attacks a CD19+ precursor, or MM cells express CD19 briefly or at low levels and get killed off.

  • You should know the truth about CANCER. There are so many different therapies & drugs out there, far better to avoid Cancer. Spirit know what causes CANCER so people are not confused about it.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy